Abstract:In vitro, antituberculosis, anti‐inflammatory, antibacterial, and antifungal activities of transition metal (II) complexes having thiosemicarbazone ligands were carried out. Further, molecular docking, DFT, MESP, and ADMET studies were proposed to give new insights into the research and to support in vitro results. Infectious diseases have held a prominent place in the history of humanity, shaping societies, influencing medical advances, and affecting the lives of individuals on a global scale and are caused by a variety of pathogens that lead to a wide range of illnesses. Among this diverse group of ailments, tuberculosis (TB), inflammatory conditions, and various bacterial and fungal diseases stand out as major challenges that have long plagued humanity. Thus, the aim of this research is delve a significant combatting agent against TB, inflammation, bacterial and fungal deformities. To explore the above facts and to examine the therapeutic potential, the previously synthesized thiosemicarbazones (1–2) and their Co (II), Ni (II), Cu (II), Zn (II) complexes (3–10) of benzaldehydes and 4‐(4‐ethylphenyl)‐3‐thiosemicarbazide were proposed for in vitro investigation by microplate Alamar Blue, bovine serum albumin, and serial dilution methods. The compound (10) demonstrates almost double effectiveness in controlling TB dysfunction (minimum inhibitory concentration [MIC] value 0.006 ± 0.001 μmol/mL), surpassing streptomycin, whereas (6) and (9) have comparable TB inhibition efficacy to streptomycin. The compound (10) also has the highest potency for inflammation (6.75 ± 0.09 μM), bacterial (0.0066 μmol/mL), and fungal (0.0066 μmol/mL) ailments among the tested compounds with comparable inhibition abilities to their respective standard drugs. Moreover, molecular docking (targeting the PDB ID 6H53 and 1CX2 proteins), density functional theory (DFT), molecular electrostatic potential (MESP), and absorption, distribution, metabolism, excretion, and toxicity (ADMET) evaluations were performed against the highly efficient ligand (2) and its complexes (7–10) to validate the in vitro results. In this endeavor, our aim is to actively participate in the continuous initiatives aimed at fighting infectious diseases and enhancing global health and overall well‐being.

Cu-promoted synthesis of triclosan-Mannich and Glaser adducts: anti-mycobacterial evaluation with in silico validations

Design, Synthesis, and Anti‐Mycobacterial Evaluation of Triclosan‐Isoniazid Hybrids

Rational design and microwave-promoted synthesis of triclosan-based dimers: targeting InhA for anti-mycobacterial profiling

Design, synthesis, anti-mycobacterial activity, molecular docking and ADME analysis of spiroquinoxaline-1,2,4-oxadiazoles via [3 + 2] cycloaddition reaction under ultrasound irradiation

Exploration of isoxazole‐carboxylic acid methyl ester based 2‐substituted quinoline derivatives as promising antitubercular agents

Design, synthesis, anti-tubercular activity, and computational studies of novel 3-(quinolin-3-yl)-1-phenylprop-2-en-1-one derivatives

Synthesis and structure-activity relationships of aryl fluorosulfate-based inhibitors as novel antitubercular agents

Synthesis, Antitubercular Evaluation of New 2,3-(4-Aminobenzamido)benzoic Acid Derivatives

Synthesis, characterisation, X-ray diffraction and biological evaluation of new thiourea derivatives against Mycobacterium tuberculosis and cervical cancer

Computational investigation on the anti-tuberculosis potential of novel thiazinane derivatives

Antitubercular evaluation of dihydropyridine-triazole conjugates: design, synthesis, in vitro screening, SAR and in silico ADME predictions

Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques

Synthesis, In Vitro and In Silico Evaluation of 3-(4, 5-Diphenyl-4H-1,2,4-triazol-3-yl)pyridine Derivatives As Potential Antimicrobial Agents

Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles

Chemical synthesis and molecular modeling of novel substituted N-1,3-benzoxazol-2yl benzene sulfonamides as inhibitors of inhA enzyme and Mycobacterium tuberculosis growth

Synthesis and Biological Evaluation of Arylthiourea Derivatives with Antitubercular Activity

2,3,5‐Trisubstituted Thiazolidinone Derivatives as Potential Antimicrobial and Antitubercular Agents and In Silico Studies

Synthesis, Biological and Molecular Docking Studies of Thiazole‐Thiadiazole derivatives as potential Anti‐Tuberculosis Agents

New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis

Synthesis and Biological Evaluation of Moxifloxacin-Acetyl-1,2,3-1h-triazole-methylene-isatin Hybrids As Potential Anti-Tubercular Agents Against Both Drug-Susceptible and Drug-Resistant Mycobacterium Tuberculosis Strains.